High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy

Rong Fan; Siru Zhao; Junqi Niu; Hong Ma; Qing Xie; Yang Song; Jianping Xie; Xiaoguang Dou; Jia Shang; Huiying Rao; Qi Xia; Yali Liu; Yongfeng Yang; Hongbo Gao; Aimin Sun; Xieer Liang; Xueru Yin; Yongfang Jiang; Yanyan Yu; Jian Sun; Nikolai V. Naoumov; Jinlin Hou

doi:10.1136/gutjnl-2024-332182

Abstract

Hepatitis B surface antigen (HBsAg) loss is the optimal outcome for patients with chronic hepatitis B (CHB) but this rarely occurs with currently approved therapies. We aimed to develop and validate a prognostic model for HBsAg loss on treatment using longitudinal data from a large, prospectively followed, nationwide cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fan et al. (2024) studied this question.

synapsesocial.com/papers/68e63e32b6db6435875d0175 https://doi.org/10.1136/gutjnl-2024-332182

View Full Paper

Ask AI

Bookmark

Share

High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy

Abstract

Discussion

Cite This Study

High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy

Abstract

Discussion

Cite This Study

Keep reading

Keep reading